Drug Profile
Epoetin alfa biosimilar - Nanogen
Alternative Names: Nanokine; Recombinant human erythropoietin alfa - NanogenLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Nanogen Biopharmaceutical Co
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 04 Mar 2014 Launched for Anaemia in Vietnam (IV)
- 04 Mar 2014 Launched for Anaemia in Vietnam (SC)